Cyclooxygenase-2 Expression Is a Predictive Marker for Late Recurrence in Colorectal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung Hoo | - |
dc.contributor.author | Ahn, Byung kyu | - |
dc.contributor.author | Paik, Seung Sam | - |
dc.contributor.author | Lee, Kang Hong | - |
dc.date.accessioned | 2022-07-11T17:19:58Z | - |
dc.date.available | 2022-07-11T17:19:58Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-06 | - |
dc.identifier.issn | 1687-6121 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/149910 | - |
dc.description.abstract | Introduction. Cyclooxygenase-2 (COX-2) expression is elevated in colorectal cancer (CRC). However, data about the relation between COX-2 expression and the impact on the biologic behavior of recurrent disease are inconclusive as yet. The aim of this study is to investigate the relationship between the status of COX-2 expression in the primary CRC and the characteristics of recurrence after curative resection of stage I to III CRC. Materials and Methods. Ninety-eight patients with recurrence in 376 CRC patients, who underwent curative surgery between January 1991 and August 2001, were retrospectively assessed. Immunohistochemical staining, performed for the presence of COX-2 on tissue microarrays, was analyzed. Results. Forty-six patients showed elevated COX-2 expression, and 52 patients did not. The mean time to recurrence was significantly longer in the positive group than in the negative group (34.1 months ± 30.0 versus 21.9 months ± 17.4; P = 0 019). Positive COX-2 expression was correlated with late recurrence (>3 years after surgery) [43.5% versus 13.5%; P = 0 001]. In multivariate analysis, COX-2 expression was an independent factor associated with late recurrence (OR 4.656; 95% CI, 1.696 to 12.779; P = 0 003). Recurrence pattern and postrecurrence survival were not different between the two groups. Conclusions. Elevated COX-2 expression in itself is not a prognostic factor, but COX-2 expression in tumor tissue may be an independent predictive marker of late recurrence for patients with stage I to III CRC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | HINDAWI LTD | - |
dc.title | Cyclooxygenase-2 Expression Is a Predictive Marker for Late Recurrence in Colorectal Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ahn, Byung kyu | - |
dc.contributor.affiliatedAuthor | Paik, Seung Sam | - |
dc.contributor.affiliatedAuthor | Lee, Kang Hong | - |
dc.identifier.doi | 10.1155/2018/7968149 | - |
dc.identifier.scopusid | 2-s2.0-85056245433 | - |
dc.identifier.wosid | 000438065800001 | - |
dc.identifier.bibliographicCitation | GASTROENTEROLOGY RESEARCH AND PRACTICE, v.2018, pp.1 - 9 | - |
dc.relation.isPartOf | GASTROENTEROLOGY RESEARCH AND PRACTICE | - |
dc.citation.title | GASTROENTEROLOGY RESEARCH AND PRACTICE | - |
dc.citation.volume | 2018 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | UP-REGULATION | - |
dc.subject.keywordPlus | SURVIVIN | - |
dc.subject.keywordPlus | COX-2 | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | TARGET | - |
dc.identifier.url | https://www.hindawi.com/journals/grp/2018/7968149/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.